Last reviewed · How we verify
An Observational Study Into the Usage and Efficacy of Crestor 5mg as a Start Dosage in Achieving the LDL-C Target Level in Both Statin-naive and Treated Primary and Secondary Prevention Patients With a High Risk of a Cardiovascular Event.
Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.
Details
| Lead sponsor | AstraZeneca |
|---|---|
| Status | COMPLETED |
| Enrolment | 3840 |
| Start date | 2006-02 |
| Completion | 2009-01 |
Conditions
- Hypercholesteremia
Countries
Netherlands